Scope

• The report provides sector information broken down into detailed categories and segments in country.
• Total revenues, products sold, end users, and average pricing.
• Market shares of all the key competitors.
• Key pipeline products that are set to shape the market, broken down by sector.
• Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
• Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity investments and IPOs.
• Customer, hospitals and physicians data.

Reasons to buy

• Gain a strong understanding of the industry at a global level, with break downs for the country
• Evaluate and compare the attractiveness of the market in the country.
• Identify growth segments and opportunities in each industry sector within the country.
• Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
• Analyze the competitiveness of the market in the country and identify hotspots.
• Develop strategies based on the latest product, brand, expansion and research and development news in the country.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
• Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

1 Table of Contents 2
1.1 List of Tables 12
1.2 List of Figures 15
2 Introduction 17
2.1 What Is This Report About? 17
2.2 Definitions 17
2.2.1 Wound Care Management 17
3 Healthcare Sector Review 19
3.1 Healthcare Expenditure 19
3.2 Healthcare Infrastructure 20
3.2.1 Healthcare Personnel Data 21
3.2.2 Healthcare Facilities Data 22
3.3 Healthcare Policy 25
4 Wound Care Management in China 26
4.1 Wound Care Management Overall Revenues (2000-2012) 26
4.2 Wound Care Management Overall Volume (2000-2012) 32
4.3 Wound Care Management Overall Company Shares (2005-2006) 35
5 Wound Closure Devices in China 36
5.1 Wound Closure Devices Overall Revenues (2000-2012) 36
5.1.1 Skin Closure Devices Overall Revenues (2000-2012) 40
5.1.2 Hemostats Overall Revenues (2000-2012) 42
5.1.3 Tissue Sealants Overall Revenues (2000-2012) 44
5.2 Wound Closure Devices Overall Volume (2000-2012) 46
5.2.1 Skin Closure Devices Overall Volume (2000-2012) 48
5.2.2 Hemostats Overall Volume (2000-2012) 50
5.2.3 Tissue Sealants Overall Volume (2000-2012) 52
5.3 Wound Closure Devices Average Price (2000-2012) 54
5.3.1 Hemostats Average Price (2000-2012) 54
5.3.2 Tissue Sealants Average Price (2000-2012) 56
5.3.3 Skin Closure Devices Average Price (2000-2012) 58
5.4 Wound Closure Devices Distribution Share (2000-2012) 60
5.5 Wound Closure Devices Company Share (2000-2012) 61
6 Ostomy in China 62
6.1 Ostomy Overall Revenue (2000-2012) 62
6.2 Ostomy Overall Volume (2000-2012) 64
6.3 Ostomy Average Price (2000-2012) 66
6.4 Ostomy Distribution Share (2005-2006) 68
6.5 Ostomy Company Share (2005-2006) 69
7 Advanced Wound Management in China 70
7.1 Advanced Wound Management Overall Revenue (2000-2012) 70
7.2 Advanced Wound Management Overall Volume (2000-2012) 72
7.3 Advanced Wound Management Average Price (2000-2012) 74
7.4 Advanced Wound Management Distribution Share (2005-2006) 76
7.5 Advanced Wound Management Company Share (2005-2006) 77
8 Traditional Wound Management in China 78
8.1 Traditional Wound Management Overall Revenue (2000-2012) 78
8.2 Traditional Wound Management Overall Volume (2000-2012) 80
8.3 Traditional Wound Management Average Price (2000-2012) 82
8.4 Traditional Wound Management Distribution Share (2000-2012) 84
8.5 Traditional Wound Management Company Share (2000-2012) 85
9 Compression Therapy in China 86
9.1 Compression Therapy Category Revenue 86
9.2 Compression Therapy Category Volume (2000-2012) 88
9.3 Compression Therapy Average Price (2000-2012) 90
9.4 Compression Therapy Distribution Share (2000-2012) 92
9.5 Compression Therapy Company Share (2000-2012) 93
10 Covidien Ltd./Tyco Healthcare Company Profile 94
10.1 Company Overview 94
10.2 Business Overview 94
10.2.1 Imaging Solutions 94
10.2.2 Medical Devices 95
10.2.3 Medical Supplies 95
10.2.4 Pharmaceutical Products 96
10.2.5 Retail Products 96
10.2.6 Products 97
10.2.7 History 98
10.3 Value Chain Analysis 99
10.3.1 Manufacturing 99
10.3.2 Product Development 100
10.3.3 Sales and Marketing 101
10.4 SWOT Analysis 102
10.4.1 Covidien Ltd./Tyco Healthcare Strengths 102
10.4.2 Covidien Ltd./Tyco Healthcare Weaknesses 103
10.4.3 Covidien Ltd./Tyco Healthcare Opportunities 104
10.4.4 Covidien Ltd./Tyco Healthcare Threats 104
10.5 Financial and Operational Review 106
10.5.1 Financial Statements 106
10.5.2 Financial Ratios 107
10.6 Locations And Subsidiaries 108
10.7 Financial Deals Landscape 110
10.7.1 Covidien Signs An Agreement With Allergan 110
10.7.2 Covidien Acquires Scandius Biomedical 111
10.7.3 Covidien International Finance Completes Private Placement Of $2,750 Million 112
10.7.4 Covidien And BioSynthema Enter Into Licensing Agreement 114
10.7.5 Integra LifeSciences Acquires Assets Of Radionics Division From Covidien 115
10.7.6 Covidien To Sell European Incontinence Business 117
10.7.7 Covidien To Acquire Tissue Science Laboratories 119
10.8 Recent Developments 121
10.8.1 Mar 28, 2008: Covidien Spends $760,000 Lobbying Federal Government In 2007 121
10.8.2 Mar 18, 2008: Covidien Declares Quarterly Dividend 121
10.8.3 Feb 21, 2008: Covidien Gests Favorable Decision In Patent Litigation Case 121
10.8.4 Feb 07, 2008: Covidien Declares Q1 Fiscal 2008 Results 122
10.8.5 Jan 15, 2008: Covidien Declares Quarterly Dividend 123
10.8.6 Jan 10, 2008: Covidien To Declare Q1 Fiscal 2008 Results 124
10.8.7 Dec 06, 2007: Covidien Reports Q4 Fiscal 2007 Results 124
10.8.8 Oct 04, 2007: Covidien And NewSouth Innovations Collaborate To Develop Novel Imaging Agent   126
10.8.9 Sep 28, 2007: Covidien Declares Quarterly Dividend 126
10.8.10 Aug 09, 2007: Covidien Declares Q3 Fiscal 2007 Results 126
10.9 Covidien Ltd./Tyco Healthcare Pipeline Products 128
10.9.1 PleuraSeal Lung Sealant System 128
10.9.2 Sandman Intro CPAP Device 129
11 3M Company Profile 131
11.1 Company Overview 131
11.2 Business Overview 131
11.2.1 Consumer and Office 131
11.2.2 Display and Graphics 131
11.2.3 Electro and Communications 132
11.2.4 Health Care 133
11.2.5 Industrial and Transportation 133
11.2.6 Safety, Security and Protection Services 134
11.2.7 Products 134
11.3 Value Chain Analysis 137
11.3.1 Manufacturing 137
11.3.2 Product Development 137
11.3.3 Sales and Marketing 138
11.4 SWOT Analysis 139
11.4.1 3M Company Strengths 139
3M Company Weaknesses 140
3M Company Opportunities 140
3M Company Threats 141
11.5 Financial and Operational Review 142
11.6 Locations And Subsidiaries 143
11.7 Financial Deals Landscape 145
11.7.1 3M Canada Acquires Les Entreprises Solumed 145
11.7.2 3M Acquires Bondo 147
11.7.3 3M Acquires Lingualcare 149
11.7.4 3M Acquires Abzil Industria E Comercio 151
11.7.5 3M Acquires Neo Plast 152
11.7.6 3M Acquires Assets Of DMS Chile 154
11.7.7 3M Acquires Business Of Innovative Paper Technologies 156
11.7.8 3M Acquires Powell 158
11.7.9 Gen-Probe Signs An Agreement With 3M Company 160
11.7.10 3M Acquires Acolyte Biomedica 163
11.7.11 3M Acquires Sealed Air Corp.'S Interest In Polymask Corp. 165
11.7.12 3M Sells Its Pharmaceutical Business To Meda AB 167
11.7.13 3M Acquires SoftMed Systems 169
11.7.14 3M Sells its Pharmaceuticals Business to Graceway 171
11.7.15 Gen-Probe Signs An Agreement With 3M 173
11.7.16 3M Sells its Pharmaceutical Operations in the Asia Pacific Region to Ironbridge Capital and Archer Capital 175
11.7.17 3M Acquires Biotrace International 177
11.7.18 Ekahau Secures $16 Million In Additional Funding 179
11.7.19 3M Acquires Brontes Technologies 182
11.7.20 3M acquires Nylonge Corp 184
11.7.21 3M Signs An Agreement With ClozeX Medical 186
11.7.22 3M Acquires OMNII Oral Pharmaceuticals 188
11.7.23 3M Sells Pharmaceutical Operations In The United States To Graceway 190
11.7.24 3M Sells Pharmaceutical Business In Europe To Meda AB 193
11.7.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge  and Archer Capital 195
11.7.26 3M Acquires Accuspray Application Technologies Inc. 198
11.7.27 3M to acquire Rochford Thompson Equipment 200
11.7.28 3M To Acquire Aearo Technologies From Permira 202
11.7.29 Permira To Sell Aearo Technologies To 3M 204
11.8 Recent Developments 207
11.8.1 Mar 31, 2008: HighJump Software Introduces Survey Management Solution for Direct Store Delivery Businesses 207
11.8.2 Mar 24, 2008: Brazil's Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR for Upgrade of Line Over Parana River in Sao Paulo State 207
11.8.3 Mar 19, 2008: 3M to Headquarter Optical Systems Business in Asia 209
11.8.4 Mar 19, 2008: 3M To Headquarter Optical Systems Business In North Asia 209
11.8.5 Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year 209
11.8.6 Nov 12, 2007: 3M Declares Quarterly Dividend 209
11.8.7 Oct 24, 2007: 3M And Sanyo Settle Suit On Lithium Ion Battery 209
11.8.8 Aug 13, 2007: 3M Declares Quarterly Dividend 210
11.8.9 May 08, 2007: 3M Declares Quarterly Dividend 210
11.8.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop Rapid Molecular Tests 210
12 Smith & Nephew Plc Company Profile 211
12.1 Company Overview 211
12.2 Business Overview 211
12.2.1 Advanced Wound Management 211
12.2.2 Endoscopy 212
12.2.3 Reconstruction 212
12.2.4 Trauma and Clinical Therapies 213
12.2.5 Products 214
12.2.6 History 214
12.3 Value Chain Analysis 218
12.3.1 Manufacturing 218
12.3.2 Product Development 219
12.3.3 Sales and Marketing 220
12.4 SWOT Analysis 220
12.4.1 Smith & Nephew Plc Strengths 220
12.4.2 Smith & Nephew Plc Weaknesses 221
12.4.3 Smith & Nephew Plc Opportunities 221
12.4.4 Smith & Nephew Plc Threats 222
12.5 Financial and Operational Review 223
12.6 Locations And Subsidiaries 224
12.7 Financial Deals Landscape 226
12.7.1 Smith & Nephew Endoscopy Sells Its Vascular Business To InaVein 226
12.7.2 Smith & Nephew Signs An Agreement With Universal Hospital Services 226
12.7.3 Smith & Nephew Acquires Plus Orthopedics Holding 227
12.7.4 Smith & Nephew And Teknimed Enter Into Distribution Agreement 229
12.7.5 Smith & Nephew Acquires BlueSky Medical Group 230
12.7.6 Smith & Nephew Enters Into An Agreement With Covalon 231
12.7.7 Smith & Nephew Signs An Agreement With UDL Laboratories 232
12.7.8 Nexa Orthopedics Signs An Agreement  With Smith & Nephew 233
12.7.9 Smith & Nephew Acquires Osteobiologics 233
12.7.10 Smith & Nephew And Q-MED Enter Into Licensing Agreement 234
12.7.11 Smith & Nephew Completes Sale Of 50% Interest In BSN Medical To Montagu Private Equity   236
12.7.12 ArthroCare Enters Into Licensing Agreement With Smith & Nephew 237
12.7.13 Smith & Nephew Signs Licensing Agreement With Alexandria Research Technologies 238
12.7.14 Smith & Nephew Signs An Agreement With ORTHOsoft 239
12.7.15 Osteotech And Smith & Nephew Enter Into Processing And Distribution Agreement 240
12.7.16 Smith & Nephew Acquires VERSAJET From HydroCision 241
12.7.17 Smith & Nephew Terminates Acquisition Of Biomet 242
12.8 Recent Developments 243
12.8.1 Apr 02, 2008: Smith & Nephew Declares Second Interim Dividend 243
12.8.2 Apr 02, 2008: Smith & Nephew Reports 2007 Results 243
12.8.3 Mar 23, 2008: Smith & Nephew, Corin Battle To Win Over America’s Hip Generation 244
12.8.4 Feb 29, 2008: Smith & Nephew Appoints SVP, GM 245
12.8.5 Feb 20, 2008: Smith & Nephew and Synthes Settle Patent Dispute For Trochanteric Fixation Nails 246
12.8.6 Oct 22, 2007: Smith & Nephew Declares Interim Dividend 246
12.8.7 May 03, 2007: Smith & Nephew Appoints New CEO 246
12.9 Smith & Nephew Plc Pipeline Products 248
12.9.1 R3 Modular resurfacing Acetabular system 248
12.9.2 R3 Ceramic-on-ceramic Acetabular System 248
13 Baxter International  Company Profile 249
13.1 Company Overview 249
13.2 Business Overview 249
13.2.1 BioScience 249
13.2.2 Medication Delivery 249
13.2.3 Renal 250
13.2.4 Products 250
13.2.5 History 251
13.3 Value Chain Analysis 254
13.3.1 Manufacturing 254
13.3.2 Product Development 254
13.3.3 Sales and Marketing 255
13.4 SWOT Analysis 256
13.4.1 Baxter International Inc. Strengths 256
13.4.2 Baxter International Inc. Weaknesses 257
13.4.3 Baxter International Inc. Opportunities 257
13.4.4 Baxter International Inc. Threats 257
13.5 Financial and Operational Review 259
13.6 Locations And Subsidiaries 261
13.7 Financial Deals Landscape 263
13.7.1 Baiyunshan And Baxter Form A Joint Venture In China 263
13.7.2 Baxter Signs Licensing Agreement With Intercytex And Spinal Restoration 264
13.7.3 Baxter Sells Transfusion Therapies Business to Texas Pacific and Maverick Capital 266
13.7.4 B. Braun Acquires Renal Therapy Business Of Baxter 268
13.7.5 Innovata signs a license agreement with Baxter International 269
13.7.6 Kuros Biosurgery Signs An Agreement With Baxter International 271
13.7.7 Gambro Signs An Agreement With Baxter 272
13.7.8 Baxter Healthcare And Gambro Enter Into An Agreement 274
13.7.9 Baxter and Cerus Enter Into Agreement With BioOne for Commercialization Of INTERCEPT Blood System 275
13.7.10 Baxter International And Kaketsuken Enter Into Agreement 277
13.7.11 Baxter To Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful 278
13.8 Recent Developments 280
13.8.1 Jan 24, 2008: Baxter Achieves Record Sales and Earnings for Full-Year 2007 280
13.8.2 Dec 18, 2007: Baxter Elects CFO 282
13.8.3 Nov 13, 2007: Baxter Declares Quarterly Dividend 282
13.8.4 Aug 01, 2007: Baxter Elects New Board Director 283
13.8.5 Jul 31, 2007: Baxter Announces Quarterly Dividend 283
13.8.6 Mar 13, 2007: Baxter Declares Additional Share Repurchase Authorization 283
13.8.7 Feb 13, 2007: Baxter Announces Quarterly Dividend 284

List of Tables

1.1 List of Tables
Table 1: Doctors by Specialty in China, 2003-2007 21
Table 2: Hospital Wards by Specialty in China, 2003 - 2007 22
Table 3: Healthcare Institutions in China, 2000-2004 23
Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2004 23
Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2004 24
Table 6: Wound Care Management, China, Overall Revenues ($ mn), 2000-2012 26
Table 7: Wound Care Management, China, Overall Revenues ($ mn), Historic, 2000-2007 27
Table 8: Wound Care Management, China, Overall Revenues ($ mn), Forecast, 2007-2012 28
Table 9: Wound Care Management, China, Category Revenues ($ mn), 2000-2012 29
Table 10: Wound Care Management, China, Category Revenues ($ mn), Historic, 2000-2007 30
Table 11: Wound Care Management, China, Category Revenues ($ mn), Forecast, 2007-2012 31
Table 12: Wound Care Management, China, Category Volume (Units), 2000-2012 32
Table 13: Wound Care Management, China, Category Volume (Units), Historic, 2000-2007 33
Table 14: Wound Care Management, China, Category Volume (Units), Forecast, 2007-2012 34
Table 15: Wound Care Management, China, Overall Company Share by Revenue ($ mn), 2005-2006 35
Table 16: Wound Closure Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 36
Table 17: Wound Closure Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 37
Table 18: Wound Closure Devices, China, Revenue by Segment ($ mn), Historic, 2000-2007 38
Table 19: Wound Closure Devices, China, Revenue by Segment ($ mn), Forecast, 2007-2012 39
Table 20: Skin Closure Devices, China, Overall Revenues ($ mn), Historic, 2000-2007 40
Table 21: Skin Closure Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012 41
Table 22: Hemostats, China, Overall Revenues ($ mn), Historic, 2000-2007 42
Table 23: Hemostats, China, Overall Revenues ($ mn), Forecast, 2007-2012 43
Table 24: Tissue Sealants, China, Overall Revenues ($ mn), Historic, 2000-2007 44
Table 25: Tissue Sealants, China, Overall Revenues ($ mn), Forecast, 2007-2012 45
Table 26: Wound Closure Devices, China, Overall Volume (Units), Historic, 2000-2007 46
Table 27: Wound Closure Devices, China, Overall Volume (Units), Forecast, 2007-2012 47
Table 28: Skin Closure Devices, China, Overall Volume (Units), Historic, 2000-2007 48
Table 29: Skin Closure Devices, China, Overall Volume (Units), Forecast, 2007-2012 49
Table 30: Hemostats, China, Overall Volume (Units), Historic, 2000-2007 50
Table 31: Hemostats, China, Overall Volume (Units), Forecast, 2007-2012 51
Table 32: Tissue Sealants, China, Overall Volume (Units), Historic, 2000-2007 52
Table 33: Tissue Sealants, China, Overall Volume (Units), Forecast, 2007-2012 53
Table 34: Hemostats, China, Average Price ($), Historic, 2000-2007 54
Table 35: Hemostats, China, Average Price ($), Forecast, 2007-2012 55
Table 36: Tissue Sealants, China, Average Price ($), Historic, 2000-2007 56
Table 37: Tissue Sealants, China, Average Price ($), Forecast, 2007-2012 57
Table 38: Skin Closure Devices, China, Average Price ($), Historic, 2000-2007 58
Table 39: Skin Closure Devices, China, Average Price ($), Forecast, 2007-2012 59
Table 40: Wound Closure Devices, China, Distribution Share by Revenue ($ mn), 2005-2006 60
Table 41: Wound Closure Devices, China, Company Share by Revenue ($ mn), 2005-2006 61
Table 42: Ostomy, China, Overall Revenues ($ mn), Historic, 2000-2007 62
Table 43: Ostomy, China, Overall Revenues ($ mn), Forecast, 2007-2012 63
Table 44: Ostomy, China, Overall Volume (Units), Historic, 2000-2007 64
Table 45: Ostomy, China, Overall Volume (Units), Forecast, 2007-2012 65
Table 46: Ostomy, China, Average Price ($), Historic, 2000-2007 66
Table 47: Ostomy, China, Average Price ($), Forecast, 2007-2012 67
Table 48: Ostomy, China, Distribution Share by Revenue ($ mn), 2005-2006 68
Table 49: Ostomy, China, Company Share by Revenue ($ mn), 2005-2006 69
Table 50: Advanced Wound Management, China, Overall Revenues ($ mn), Historic, 2000-2007 70
Table 51: Advanced Wound Management, China, Overall Revenues ($ mn), Forecast, 2007-2012 71
Table 52: Advanced Wound Management, China, Overall Volume (Units), Historic, 2000-2007 72
Table 53: Advanced Wound Management, China, Overall Volume (Units), Forecast, 2007-2012 73
Table 54: Advanced Wound Management, China, Average Price ($), Historic, 2000-2007 74
Table 55: Advanced Wound Management, China, Average Price ($), Forecast, 2007-2012 75
Table 56: Advanced Wound Management, China, Distribution Share by Revenue ($ mn), 2005-2006 76
Table 57: Advanced Wound Management, China, Company Share by Revenue ($ mn), 2005-2006 77
Table 58: Traditional Wound Management, China, Overall Revenues ($ mn), Historic, 2000-2007 78
Table 59: Traditional Wound Management, China, Overall Revenues ($ mn), Forecast, 2007-2012 79
Table 60: Traditional Wound Management, China, Overall Volume (Units), Historic, 2000-2007 80
Table 61: Traditional Wound Management, China, Overall Volume (Units), Forecast, 2007-2012 81
Table 62: Traditional Wound Management, China, Average Price ($), Historic, 2000-2007 82
Table 63: Traditional Wound Management, China, Average Price ($), Forecast, 2007-2012 83
Table 64: Traditional Wound Management, China, Distribution Share by Revenue ($ mn), 2005-2006 84
Table 65: Traditional Wound Management, China, Company Share by Revenue ($ mn), 2005-2006 85
Table 66: Compression Therapy, China, Overall Revenues ($ mn), Historic, 2000-2007 86
Table 67: Compression Therapy, China, Overall Revenues ($ mn), Forecast, 2007-2012 87
Table 68: Compression Therapy, China, Overall Volume (Units), Historic, 2000-2007 88
Table 69: Compression Therapy, China, Overall Volume (Units), Forecast, 2007-2012 89
Table 70: Compression Therapy, China, Average Price ($), Historic, 2000-2007 90
Table 71: Compression Therapy, China, Average Price ($), Forecast, 2007-2012 91
Table 72: Compression Therapy, China, Distribution Share by Revenue ($ mn), 2005-2006 92
Table 73: Compression Therapy, China, Company Share by Revenue ($ mn), 2005-2006 93
Table 74:      Covidien Ltd./Tyco Healthcare, SWOT Analysis, 2007 102
Table 75:      Covidien Ltd./Tyco Healthcare, Financial Statements, USD Million, 2003-2007 106
Table 76:      Covidien Ltd./Tyco Healthcare, Financial Ratios, USD Million, 2003-2007 107
Table 77:      Covidien Ltd./Tyco Healthcare, Other Locations 108
Table 78:      Covidien Ltd./Tyco Healthcare, Subsidiaries 109
Table 79:      3M Company, SWOT Analysis, 2006 139
Table 80:      3M Company, Financial Statements, USD Million, 2002-2006 142
Table 81:      3M Company, Financial and Operational Overview, USD Million, 2002-2006 143
Table 82:      3M Company, Subsidiaries 144
Table 83:      Smith & Nephew Plc, SWOT Analysis, 2006 220
Table 84:      Smith & Nephew Plc, Financial Statements, USD Million, 2002-2006 223
Table 85:      Smith & Nephew Plc, Financial Ratios, USD Million, 2002-2006 224
Table 86:      Smith & Nephew Plc, Other Locations 225
Table 87:      Baxter International Inc., SWOT Analysis, 2006 256
Table 88:      Baxter International Inc., Financial Statements, USD Million, 2002-2006 259
Table 89:      Baxter International Inc., Financial Ratios, USD Million, 2002-2006 260
Table 90:      Baxter International Inc., Other Locations 261
Table 91:      Baxter International Inc., Subsidiaries 262
Table 92:      HARTMANN GROUP, SWOT Analysis, 2006 293
Table 93:      HARTMANN GROUP, Financial Statements, Euro Thousand, 2002-2006 296
Table 94:      HARTMANN GROUP, Financial Ratios, Euro Thousand, 2002-2006 297
Table 95:      HARTMANN GROUP, Subsidiaries 298
Table 96:   Currency Conversion from USD to Local Currency at 2007 Constant Rate 315